JavaScript is disabled in your browser. Please enable JavaScript to view this website.

FN1

GeneName

FN1

Summary

FN1, also known as fibronectin or CIG, is a 272kDa glycoprotein that plays a critical role in cell adhesion and the formation of the extracellular matrix. It is expressed in various tissues, particularly at the apical plasma membrane, basement membrane, and within the extracellular matrix. FN1 is involved in numerous biological processes, including angiogenesis, wound healing, and cell-matrix adhesion. It binds to collagen, integrins, and proteoglycans, facilitating cellular interactions and signalling. This protein is secreted into the extracellular space and is found in blood microparticles and exosomes, indicating its involvement in intercellular communication and tissue repair.

Importance

FN1 is relevant to: - Tissue engineering and regenerative medicine due to its role in promoting cell adhesion and migration. - Cancer research, as it is implicated in tumour progression and metastasis through its involvement in angiogenesis and cell migration. - Cardiovascular diseases, given its influence on endothelial cell function and heart development. - Wound healing processes, where it contributes to tissue repair and regeneration by mediating cell-matrix interactions.

Top Products

For researchers investigating FN1, we recommend two excellent primary antibodies that cater to various applications. The first is the highly regarded polyclonal antibody, Anti-Fibronectin antibody (ab2413), which has garnered an impressive 1289 citations, reflecting its reliability and trust within the scientific community. This antibody is well-suited for Western blotting (WB), immunohistochemistry (IHC), and immunocytochemistry (ICC).In addition, we offer the recombinant antibody, Anti-Fibronectin antibody [F1] (ab32419). This product has been validated for use in WB, IHC, ICC, and flow cytometry (FC), making it a versatile choice for researchers seeking consistent performance across multiple applications. With 123 citations, it is also gaining recognition in the field. Together, these antibodies provide robust options for studying FN1 effectively. The Human Fibronectin Matched Antibody Pair Kit (ab222262) is an excellent option for researchers looking to study FN1 with precision.

Abcam Product Citation Summary

The data indicates a significant focus on the role of FN1 (Fibronectin 1) in various biological contexts, particularly in fibrosis, cancer, and tissue remodeling. The use of Abcam antibody ab2413 across multiple species, including human and mouse, highlights its versatility in research. Studies often involve Western blotting and immunofluorescence applications, suggesting a strong interest in protein expression and localization in pathological conditions.

Abcam Product Citation Table

Product Code
Species
Application
Study Context
PMID
ab2413
Mouse
WB, ICC-IF
Effects of losartan treatment on fibrosis-associated proteins
26194911
ab2413
Mouse
WB
Fibronectin protein turnover
26750654
ab2413
Human
WB
Glioma
29142297
ab2413
Human
IF
Epithelial-to-mesenchymal transition
28829370
ab2413
Human
WB
Epithelial-to-mesenchymal transition
28829370
ab2413
Mouse
IF, IHC
ECM interactions
27126736
ab2413
Mouse
IF, IHC
Arterial remodelling
27126736
ab2413
Mouse
WB
Myofibroblast differentiation
28098218
ab2413
Mouse
WB
Myofibroblast differentiation
28098218
ab2413
Mouse
WB
db/db mice
27585918
ab2413
Human
IF
PSCs under ATRA treatment
27375161
ab2413
Human
WB
A549 and H1299 cells
28423676
ab2413
Human
WB
High glucose treatment
31949205
ab2413
Human
WB
Effects of a Syk inhibitor
31949205
ab2413
Rat
WB
Hearts post-MI
31969558
ab2413
Rat
WB
Renal fibrosis
31949466
ab2413
Mouse
IHC-IF
Epithelial rudiments and surrounding stroma
31652655
ab2413
Mouse
WB
Fibroblast-to-myofibroblast transition
31405028
ab2413
Human
WB
Triple-negative breast cancer
31295851
ab2413
Mouse
WB
Cardiac remodeling
31405028
ab2413
Mouse
WB
Epithelial-to-mesenchymal transition in cancer
31226820
ab2413
Mouse
WB
Fibronectin knockdown effects
31226820
ab2413
Rat
WB
Fibrosis
27351287
ab2413
Rat
WB
Kidney tissues
27351287
ab2413
Rat
WB
High glucose-induced fibrosis
27351287
ab2413
Rat
WB
Effects of PPARγ on gene expression
27351287
ab2413
Rat
WB
Renal fibrosis
31392659
ab2413
Rat
WB, IHC
Pulmonary fibrosis
30755599
ab2413
Rat
WB
Fibrogenesis
30755599
ab2413
Human
WB
Crohn's disease
31973719
ab2413
Human
WB
Fibronectin expression in ovarian cancer spheroids
32429240
ab2413
Human
WB
Fibrosis markers following UUO
32306980
ab2413
Human
IHC
Fibrosis
32235811
ab2413
Human
IHC
Effects of vitamin D
32235811
ab2413
Human
IHC
Mechanical stretching effects
32235811
ab2413
Human
WB
Effects of TGF-β1
32235811
ab2413
Rat
WB
Effects of melatonin on TGF-β1-induced proliferation
31906396
ab2413
Rat
WB
Effects of melatonin on TGF-β1-stimulated proliferation and activation
31906396
ab2413
Human
IF
Extracellular matrix components
31959784
ab2413
Human
IF
ECM damage
31959784
ab2413
Human
IF
Effects of the MPO-H2O2-Cl− system
31959784
ab2413
Mouse
WB
Fibrotic markers in T1DM mice
31680453
ab2413
Mouse
WB
ECM deposition
31929748
ab2413
Rat
WB
Renal fibroblast activation
31929748
ab2413
Mouse
WB
Fibrogenic activation
31547873
ab2413
Human
FC
Cardiac fibroblasts
31438862
ab2413
Mouse
WB, ICC-IF
Fibrotic remodeling
26194911
ab2413
Mouse
IHC-IF
Smooth muscle differentiation
23744273
ab2413
Human
WB
Effects of Pirfenidone on TGF-β1 damage
32448163
ab2413
Mouse
WB
Pulmonary fibrosis
32448163
ab2413
Mouse
IHC
Glioblastoma
32183406
ab2413
Human
WB
TGF-β1-induced fibrogenic activation
31547873
ab2413
Human
WB, IHC
Endothelial cell markers in the context of fibrosis
32235811
ab2413
Human
WB, ICC-IF
Gastric cancer cell invasion and epithelial-mesenchymal transition
32827244
ab2413
Human
WB
UTSM cell line
28815060
ab2413
Mouse
IHC
Renal injury
33015191
ab2413
Mouse
WB
Subretinal fibrosis in a CNV model
33438362
ab2413
Mouse
WB
Hypoxia-induced epithelial-mesenchymal transition
33438362
ab2413
Mouse
WB
TGF-β1 induced profibrogenic plasticity
33931588
ab2413
Mouse
WB
Atherosclerotic plaque formation
27665711
ab2413
Mouse
WB
Secretory proatherogenic proteins
27665711
ab2413
Human
WB
Effects of linezolid
28600981
ab2413
Human
WB
Tumor formation and metastasis
31307515
ab2413
Human
WB
Tumor formation and metastasis
31307515
ab2413
Human
WB
Tumor formation and metastasis
31307515
ab2413
Human
WB
Effects of M2 macrophage-derived exosomes
31307515
ab2413
Human
WB
Pancreatic ductal adenocarcinoma (PDAC)
31307515
ab2413
Human
WB
Pancreatic ductal adenocarcinoma (PDAC)
31307515
ab2413
Human
WB
Pancreatic ductal adenocarcinoma (PDAC)
31307515
ab2413
Human
WB
Pancreatic ductal adenocarcinoma (PDAC)
31307515
ab2413
Human
WB
IL-24 treatment
34078403
ab2413
Human
WB
Epithelial-to-mesenchymal transition
35484165
ab2413
Mouse
WB
Fibrosis
37051024
ab2413
Mouse
IHC-IF
Diabetic kidney disease
36522378
ab2413
Mouse
WB, IHC-IF
Diabetic kidney disease
36522378
ab32419
Human
WB
Epithelial-mesenchymal transition
31801938
ab32419
Human
WB
Nasopharyngeal carcinoma
31189740
ab32419
Mouse
WB
Cell sheets
29106032
ab45688
Rat
WB
High glucose-induced EMT and Notch2 activation
31948095
ab45688
Rat
IHC-IF
ECM composition of the pancreatic acellular scaffold
29719565
ab45688
Mouse
WB, IHC
EAE-induced bladder fibrosis
33287818
ab45688
Rat
WB
High glucose-mediated activation of EMT
31948095
ab45688
Rat
WB
EMT induced by NICD2 overexpression
31948095
ab45688
Rat
IHC, IF
ECM composition of pancreatic acellular scaffolds
29719565
ab6584
Pig
IHC
Vitreoretinal architecture and extracellular matrix distribution
29214073

Developmental stage

Expressed between 12 and 19 weeks post-conception (WPC) in Bruch's membrane, with expression in the choroid evident from 14 WPC onwards (at protein level) (PubMed:29777959). Expressed in the inner limiting membrane at 17 WPC (at protein level) (PubMed:29777959). Ugl-Y1, Ugl-Y2 and Ugl-Y3 are present in the urine from 0 to 17 years of age (PubMed:17614963, PubMed:3584091).

Function

Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin (PubMed:3024962, PubMed:3593230, PubMed:3900070, PubMed:7989369). Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape (PubMed:3024962, PubMed:3593230, PubMed:3900070, PubMed:7989369). Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization (By similarity). Participates in the regulation of type I collagen deposition by osteoblasts (By similarity). Acts as a ligand for the LILRB4 receptor, inhibiting FCGR1A/CD64-mediated monocyte activation (PubMed:34089617).

Anastellin

Binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.

Secreted by contracting muscle, induces liver autophagy, a degradative pathway for nutrient mobilization and damage removal, and systemic insulin sensitization via hepatic ITGA5:ITGB1 integrin receptor signaling.

Involvement in disease

Glomerulopathy with fibronectin deposits 2

GFND2

Genetically heterogeneous autosomal dominant disorder characterized clinically by proteinuria, microscopic hematuria, and hypertension that leads to end-stage renal failure in the second to fifth decade of life.

None

The disease is caused by variants affecting the gene represented in this entry.

Spondylometaphyseal dysplasia, corner fracture type

SMDCF

An autosomal dominant form of spondylometaphyseal dysplasia, a group of short stature disorders distinguished by abnormalities in the vertebrae and the metaphyses of the tubular bones. SMDCF is characterized by flake-like, triangular, or curvilinear ossification centers at the edges of irregular metaphyses that simulate fractures. These corner fractures involve the distal tibia, the ulnar aspect of the distal radius, the proximal humerus, and the proximal femur. They represent irregular ossification at the growth plates and secondary ossification centers.

None

The disease is caused by variants affecting the gene represented in this entry.

Post-translational modifications

Sulfated.

It is not known whether both or only one of Thr-2155 and Thr-2156 are/is glycosylated.

Forms covalent cross-links mediated by a transglutaminase, such as F13A or TGM2, between a glutamine and the epsilon-amino group of a lysine residue, forming homopolymers and heteropolymers (e.g. fibrinogen-fibronectin, collagen-fibronectin heteropolymers).

Phosphorylated by FAM20C in the extracellular medium.

Proteolytic processing produces the C-terminal NC1 peptide, anastellin.

Some lysine residues are oxidized to allysine by LOXL3, promoting fibronectin activation and matrix formation.

Serotonylated on Gln residues by TGM2 in response to hypoxia.

Tissue Specificity

Expressed in the inner limiting membrane and around blood vessels in the retina (at protein level) (PubMed:29777959). Plasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular FN (dimeric or cross-linked multimeric forms), made by fibroblasts, epithelial and other cell types, is deposited as fibrils in the extracellular matrix. Ugl-Y1, Ugl-Y2 and Ugl-Y3 are found in urine (PubMed:17614963).

Cellular localization

Alternative names

FN, FN1, Fibronectin, Cold-insoluble globulin, CIG

swissprot:P02751 omim:135600 entrezGene:2335

Other research areas